Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.

被引：0

作者：

Damaj, Gandhi Laurent

Hampp, Christian

Bachy, Emmanuel

Prochazka, Katharina

Jo, Jae-Cheol

Kim, Tae Min

Oberic, Lucie

Townsend, William

Jalbert, Jessica J.

Ma, Qiufei

Kamat, Siddhesh

Wang, Joy

Ambati, Srikanth R.

Mohamed, Hesham

Chaudhry, Aafia

Thorley, Eileen

Rippin, Gerd

Harnett, James

Thieblemont, Catherine

机构：

[1] Univ Hosp Sch Med, Hematol Clin, Inst Hematol, Caen, France

[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[3] Hosp Civils Lyon, Dept Hematol, Lyon, France

[4] Univ Claude Bernard Lyon 1, Lyon, France

[5] Med Univ Graz, Univ Clin Internal Med, Dept Clin Hematol, Graz, Austria

[6] Univ Ulsan, Coll Med, Dept Hematol & Oncol, Ulsan Univ Hosp, Ulsan, South Korea

[7] Seoul Natl Univ Hosp, Seoul, South Korea

[8] Inst Univ Canc, Dept Hematol, Toulouse, France

[9] Univ Coll London Hosp, Canc Res UK, London, England

[10] Univ Coll London Hosp, UCL Canc Trials Ctr, London, England

[11] IQVIA Inc, Durham, NC USA

[12] IQVIA, Frankfurt, Germany

[13] Univ Paris Cite, Paris, France

[14] Hop St Louis, AP HP, Hematooncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19067

引用

页数：1

共 50 条

[1] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
Peters, Anthea
Nowakowski, Grzegorz S.
Dabas, Rosy
Amoloja, Theresa
Xue, Zhenyi
Koch, Caroline
Waltl, Eva E.
Fleury, Isabelle
[J]. BLOOD, 2022, 140 : 3811 - 3813
[2] Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
Thieblemont, Catherine
Ma, Qiufei
Hampp, Christian
Harnett, James
Sober, Rachel E.
Jalbert, Jessica J.
Quek, Ruben G. W.
Wei, Wenhui
Wu, Ning
Mastey, Vera
Wang, Joy
Bajwa, Anit
Maissenhaelter, Benedikt
van Gils, Chantal
Aggarwal, Shivani
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Bachy, Emmanuel
Damaj, Gandhi Laurent
[J]. BLOOD, 2022, 140 : 8065 - 8067
[3] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.
Luminari, Stefano
Harnett, James
Thieblemont, Catherine
Prochazka, Katharina
Townsend, William
Radford, John
Serna, Angel
Jalbert, Jessica J.
Kamat, Siddhesh
Wang, Joy
Ambati, Srikanth R.
Mohamed, Hesham
Chaudhry, Aafia
Sanz, Hector
Hermans, Ruben
Maissenhaelter, Benedikt
Hampp, Christian
Bachy, Emmanuel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel
Andreadis, C.
Tam, C. S.
Borchmann, P.
Jaeger, U.
McGuirk, J. P.
Holte, H.
Waller, E. K.
Jaglowski, S.
Bishop, M. R.
Foley, S. R.
Westin, J. R.
Fleury, I
Ho, P. J.
Mielke, S.
Teshima, T.
Salles, G. A.
Schuster, S. J.
Bachanova, V
Maziarz, R. T.
Besien, K., V
Izutsu, K.
Wagner-Johnston, N. D.
Kato, K.
Corradini, P.
Tiwari, R.
Awasthi, R.
Lawniczek, T.
Eldjerou, L. K.
Kersten, M. J.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 62 - 63
[6] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Bell, Jill A.
Cherepanov, Dasha
Revicki, Dennis
Speck, Rebecca M.
Swett, Laura
Stumpo, Kate
Rong, Yuanxin
Gordon, Leo I.
[J]. QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
[7] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
Saverno, Kimberly
Savill, Kristin M. Zimmerman
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Gordon, Sarah
Amoloja, Theresa
Llorente, Mae
Epperla, Narendranath
Nastoupil, Loretta J.
[J]. BLOOD, 2023, 142
[8] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[9] Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience
Manji, Farheen
Stewart, Douglas A.
[J]. BLOOD, 2020, 136
[10] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
Fitzgerald, Lindsey
Kittai, Adam
Nastoupil, Loretta J.
Waller, Alexandra
Jacobson, Caron A.
Saucier, Anna
Kamdar, Manali K.
Spradley, Janet
Denlinger, Nathan
Chipman, Jonathan
Hu, Boyu
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →